LIDDS: NanoZolid® technology presented at Pharma R&D congress in Paris
Pharma R&D 2019 attracted a large number of academic and pharmaceutical industry delegates interested in finding new drug delivery technologies for drug products. LIDDS presented the NanoZolid® technology, its project portfolio and the company's ability to formulate a broad range of pharmaceutical substances.
The Pharma R&D congress, organized by the United Scientific Group from Texas, USA, invited speakers including Associate Professor Niklas Axén, Inventor and Head of Technology and Patents at LIDDS.
-LIDDS puts effort into participating in drug delivery congresses to broaden knowledge and understanding about NanoZolid® Technology in the academic and pharma industry communities, says Dr. Axén.
The NanoZolid® technology has strong patent protection in all major markets and can be used for the life cycle management of drugs with patents that have expired or will expire in the near future. The technology is patented until 2037 in Europe, offering another 18 years of additional protection for drugs that are reformulated for the local treatment of diseases. In the rest of the world, patent protection lasts until 2030.
For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, firstname.lastname@example.org
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com